OrthoPediatrics Corp. $KIDS Shares Bought by Paradigm Capital Management Inc. NY

Key Points

• Paradigm Capital Management Inc. significantly increased its holdings in OrthoPediatrics Corp. by 1,607% during the first quarter, acquiring an additional 160,700 shares to own 170,700 shares valued at approximately $4.2 million.
• CFO Fred Hite purchased 5,076 shares of OrthoPediatrics, raising his ownership to 213,065 shares, amid a general trend of increased institutional investment in the company.
• Analysts have a favorable outlook for OrthoPediatrics, with a consensus rating of "Moderate Buy" and an average target price of $34.14, despite recent fluctuations in share price.

Paradigm Capital Management Inc. NY raised its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 1,607.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 170,700 shares of the company's stock after acquiring an additional 160,700 shares during the quarter. Paradigm Capital Management Inc. NY owned 0.70% of OrthoPediatrics worth $4,204,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Brown Advisory Inc. lifted its stake in OrthoPediatrics by 6.2% during the first quarter. Brown Advisory Inc. now owns 1,628,747 shares of the company's stock valued at $40,116,000 after buying an additional 94,719 shares in the last quarter. Wellington Management Group LLP increased its holdings in OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock worth $24,601,000 after buying an additional 178,078 shares during the last quarter. Vanguard Group Inc. increased its holdings in OrthoPediatrics by 1.5% in the first quarter. Vanguard Group Inc. now owns 937,969 shares of the company's stock worth $23,102,000 after buying an additional 14,079 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in OrthoPediatrics by 29.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock worth $15,576,000 after buying an additional 152,681 shares during the last quarter. Finally, AWM Investment Company Inc. grew its holdings in OrthoPediatrics by 14.8% during the fourth quarter. AWM Investment Company Inc. now owns 516,794 shares of the company's stock valued at $11,979,000 after purchasing an additional 66,779 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of the firm's stock in a transaction on Thursday, August 21st. The shares were purchased at an average price of $19.41 per share, for a total transaction of $98,525.16. Following the completion of the purchase, the chief financial officer directly owned 213,065 shares of the company's stock, valued at approximately $4,135,591.65. This represents a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 32.70% of the stock is owned by corporate insiders.

OrthoPediatrics Stock Down 0.4%

KIDS opened at $21.36 on Friday. OrthoPediatrics Corp. has a fifty-two week low of $16.59 and a fifty-two week high of $33.14. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43. The firm's fifty day moving average price is $21.13 and its two-hundred day moving average price is $22.12. The company has a market capitalization of $535.50 million, a P/E ratio of -11.93 and a beta of 1.12.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. The firm had revenue of $61.08 million for the quarter, compared to the consensus estimate of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on KIDS shares. BTIG Research lowered their price target on OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. JMP Securities set a $35.00 price target on OrthoPediatrics and gave the company a "market outperform" rating in a report on Friday, August 8th. Piper Sandler lowered their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Wall Street Zen upgraded OrthoPediatrics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Citigroup restated a "market outperform" rating on shares of OrthoPediatrics in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $34.14.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.